StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN – Free Report) in a research note released on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, Bank of America cut shares of FibroGen from a neutral rating to an underperform rating and cut their price objective for the stock from […]